

Supplementary material. Most common adverse events by disease and treatment.

	Rheumatoid arthritis				Spondyloarthritis			
	TNFi		JAKi		TNFi		JAKi	
	n	%	n	%	n	%	n	%
Mortality	28	100	19	100	14	100	1	100
Infections								
Lower respiratory tract	2	7.1	2	10.5	2	14.2	0	0
Endocarditis	1	3.5	0	0	0	0	0	0
Urinary tract	0	0	2	10.5	0	0	0	0
SARS-Cov-19	0	0	3	15.7	0	0	0	0
Cardiovascular								
Myocardial infarction	2	7.1	0	0	1	7.1	0	0
Cerebral ischemia/infarction	0	0	0	0	1	7.1	0	0
Intracerebral hemorrhage	1	3.5	1	5.2	0	0	1	100
Congestive heart failure	1	3.5	1	5.2	1	7.1	0	0
Intestinal ischemia	1	3.5	0	0	1	7.1	0	0
Hypertensive emergency	0	0	0	0	0	0	0	0
Solid tumors								
Lung	4	14.2	0	0	1	7.1	0	0
Colorectal	3	10.7	1	5.2	1	7.1	0	0
Brain	1	3.5	0	0	0	0	0	0
Pancreatic	0	0	0	0	1	7.1	0	0
Bladder	0	0	0	0	0	0	0	0
Chronic kidney disease	1	3.5	0	0	1	7.1	0	0
Respiratory failure	1	3.5	0	0	0	0	0	0
Infections								
Upper respiratory tract	271	18.9	101	11.3	307	17.4	12	12.7
Urinary tract	177	12.4	96	10.7	182	10.3	16	17.2
SARS-Cov-2	148	10.3	99	11.1	220	12.5	13	13.8
Lower respiratory tract	107	7.4	73	8.2	132	7.5	5	5.3
Herpes zoster	99	6.9	99	11.1	92	5.2	11	11.7
Dental abscess	42	2.9	13	1.4	40	2.2	2	2.1
Pneumonia	32	2.2	19	2.1	21	1.1	0	0
Acute gastroenteritis	31	2.1	21	2.3	44	2.5	1	1.0
Acute conjunctivitis	29	2.0	15	1.6	48	2.7	1	1.0
Skin and soft tissues	16	1.1	10	1.1	18	1.0	3	3.1
Serious infections								
SARS-Cov-19	35	17.5	31	19.8	49	25.2	4	57.1
Pneumonia	36	18.0	22	14.1	26	13.4	0	0
Upper respiratory tract	20	10.0	26	16.6	33	17.1	1	14.2
Lower respiratory tract	11	5.5	9	5.7	4	2.0	0	0
Urinary tract	3	1.5	7	4.4	6	3.0	0	0

Osteomyelitis/septic arthritis	11	5.5	4	2.5	1	0.5	0	0
Skin and soft tissues	13	6.5	10	6.4	4	2.0	1	14.2
Bacteremia	3	1.5	1	0.6	5	2.5	0	0
Herpes zoster	4	2.0	2	1.2	3	1.5	0	0
Tuberculosis	3	1.5	1	0.6	1	0.5	0	0
Malignancy								
Basal cell carcinoma	21	16.4	12	19.0	15	10.8	0	0
Lung cancer	9	7.0	7	11.1	3	2.1	0	0
Breast cancer	8	6.2	5	7.9	8	5.7	1	25.0
Urinary tract cancer	7	5.4	2	3.1	4	2.8	0	0
Pancreatic	4	3.1	4	6.3	1	0.7	0	0
Malignant melanoma	5	3.9	0	0	4	2.8	0	0
Squamous cell carcinoma	3	2.3	2	3.1	3	2.1	1	25.0
Multiple myeloma	3	2.3	3	4.7	2	1.4	0	0
Lymphoma	2	1.5	2	3.1	2	1.4	0	0
Colorectal	3	2.3	0	0	4	2.8	0	0
Prostate cancer	1	0.7	1	1.5	4	2.8	0	0
Cardiovascular								
Atrial fibrillation	12	19.0	7	13.7	11	12.9	0	0
Tachyarrhythmia	15	23.8	11	21.5	15	17.6	1	33.3
Chest pain	9	14.2	7	13.7	18	21.1	0	0
Myocardial infarction	7	11.1	3	5.8	11	12.9	1	0
Pericarditis	7	11.1	9	17.6	2	2.3	0	33.3
Heart failure	6	9.5	7	13.7	3	3.5	0	0
Angina pectoris	3	4.7	3	5.8	11	12.9	1	33.3
Lung								
Cold	93	47.9	63	51.2	138	60.7	9	81
Dyspnea	22	11.3	13	10.5	22	9.6	0	0
Cough	7	3.6	6	4.8	2	0.8	0	0
Pulmonary embolism/thrombosis	5	2.5	6	4.8	4	1.7	0	0
Pulmonary fibrosis	3	1.5	0	0	0	0	0	0
Pleural effusion	3	1.5	2	1.6	1	0.4	0	0
Bronchiectasis	0	0	0	0	1	0.4	0	0
Epistaxis	4	2.0	6	4.8	3	1.3	0	0
Interstitial lung disease	4	2.0	4	3.2	2	0.8	0	0
Chronic obstructive lung disease	2	1.0	3	2.4	3	1.3	0	0
Gastrointestinal								
Diarrhea	50	24.8	27	26.8	75	18.6	6	28.5
Abdominal pain	24	11.9	34	21.2	37	9.2	0	0
Oropharyngeal pain	24	11.9	11	6.8	39	9.7	3	14.2
Oral ulcers	15	7.4	8	5.0	17	4.2	1	4.7
Nausea	14	6.9	14	8.7	10	2.4	1	4.7
Vomiting	11	5.4	10	6.2	13	3.2	1	4.7
Crohn disease	1	0.4	0	0	11	2.7	0	0
Gastrointestinal perforations	1	0.4	1	0.6	1	0.2	0	0

TNFi Tumour Necrosis Factor inhibitor, JAKi Janus kinase inhibitors